CCNE1 amplification	Solid Tumor	CCNE1 amplification	Solid Tumor	RP-6306 Sensitive: C2 – Inclusion Criteria RP-6306 Sensitive : C2	RP-6306 Sensitive: C2 – Inclusion Criteria RP-6306 Sensitive : C2
CCNE1 amplification	Ovarian Cancer	CCNE1 amplification	Ovarian Cancer	RP-6306 Sensitive: C2 – Inclusion Criteria RP-6306 Sensitive : C2	RP-6306 Sensitive: C2 – Inclusion Criteria RP-6306 Sensitive : C2
CCNE1 amplification	Ovarian Cancer	CCNE1 amplification	Ovarian Cancer	BLU-222 Sensitive: C2 – Inclusion Criteria BLU-222 Sensitive : C2	BLU-222 Sensitive: C2 – Inclusion Criteria BLU-222 Sensitive : C2
CCNE1 amplification	Solid Tumor	CCNE1 amplification	Solid Tumor	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
CCNE1 amplification	Ovarian Cancer	CCNE1 amplification	Ovarian Cancer	INX-315 Sensitive: C2 – Inclusion Criteria INX-315 Sensitive : C2	INX-315 Sensitive: C2 – Inclusion Criteria INX-315 Sensitive : C2
CCNE1 amplification	Ovarian Cancer	CCNE1 amplification	Ovarian Cancer	ACR-368 + LY3300054 Sensitive: C3 – Early Trials ACR-368 + LY3300054 Sensitive : C3	ACR-368 + LY3300054 Sensitive: C3 – Early Trials ACR-368 + LY3300054 Sensitive : C3
CCNE1 amplification	Ovarian Cancer	CCNE1 amplification	Ovarian Cancer	NBL-001 Sensitive: C3 – Early Trials NBL-001 Sensitive : C3	NBL-001 Sensitive: C3 – Early Trials NBL-001 Sensitive : C3
CCNE1 amplification	Ovarian Cancer	CCNE1 amplification	Ovarian Cancer	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3
CCNE1 amplification	Ovarian Cancer	CCNE1 amplification	Ovarian Cancer	carboplatin + paclitaxel Resistant: C3 – Early Trials carboplatin + paclitaxel Resistant : C3	carboplatin + paclitaxel Resistant: C3 – Early Trials carboplatin + paclitaxel Resistant : C3
CCNE1 amplification	Renal Cell Carcinoma	CCNE1 amplification	Renal Cell Carcinoma	axitinib Resistant: D – Preclinical axitinib Resistant : D	axitinib Resistant: D – Preclinical axitinib Resistant : D
CCNE1 amplification	Ovarian Cancer	CCNE1 amplification	Ovarian Cancer	MK-7965 Sensitive: D – Preclinical MK-7965 Sensitive : D	MK-7965 Sensitive: D – Preclinical MK-7965 Sensitive : D
CCNE1 amplification	Ovarian Cancer	CCNE1 amplification	Ovarian Cancer	SNS-032 Sensitive: D – Preclinical SNS-032 Sensitive : D	SNS-032 Sensitive: D – Preclinical SNS-032 Sensitive : D
CCNE1 amplification	Breast Cancer	CCNE1 amplification	Breast Cancer	CDK2 inhibitor Sensitive: D – Preclinical CDK2 inhibitor Sensitive : D	CDK2 inhibitor Sensitive: D – Preclinical CDK2 inhibitor Sensitive : D
CCNE1 amplification	Melanoma	CCNE1 amplification	Melanoma	AZD1775 Sensitive: D – Preclinical AZD1775 Sensitive : D	AZD1775 Sensitive: D – Preclinical AZD1775 Sensitive : D
CCNE1 amplification	Urothelial Cancer	CCNE1 amplification	Urothelial Cancer	AZD1775 Sensitive: D – Preclinical AZD1775 Sensitive : D	AZD1775 Sensitive: D – Preclinical AZD1775 Sensitive : D
CCNE1 amplification	Hepatocellular Cancer	CCNE1 amplification	Hepatocellular Cancer	RP-6306 Sensitive: D – Preclinical RP-6306 Sensitive : D	RP-6306 Sensitive: D – Preclinical RP-6306 Sensitive : D
CCNE1 amplification	Ovarian Cancer	CCNE1 amplification	Ovarian Cancer	APR-1051 Sensitive: D – Preclinical APR-1051 Sensitive : D	APR-1051 Sensitive: D – Preclinical APR-1051 Sensitive : D
CCNE1 amplification	Gastric Cancer	CCNE1 amplification	Gastric Cancer	INX-315 Sensitive: D – Preclinical INX-315 Sensitive : D	INX-315 Sensitive: D – Preclinical INX-315 Sensitive : D

CCNE1 amplification

Associations